ICCO .07 InterCare DX, Inc. Initiates Full Commercialization of the Vasogr
CULVER CITY, CA -- (MARKET WIRE) -- 02/24/06 -- Anthony C. Dike, MD, Chairman an
InterCare DX, Inc. (OTC BB: ICCO), announced today the appointment of
Emeritus Professor Jeff Raines as the Chairman of the Scientific Advisory
Board for the Vasogram Technology, which has now been officially introduced
to the market after almost one year of pilot testing of the product by
InterCare DX, Inc, for patient and healthcare providers acceptance.
Professor Raines' professional experience includes over forty years in
academia, having received a Doctorate degree in Mechanical Engineering from
Massachusetts Institute of Technology and Doctorate degree in medicine from
Harvard Medical School under an NIH MD/PhD Training Fellowship in 1972. He
has an extensive formal education in the areas of clinical cardiovascular
medicine with surgical exposure, engineering and research. Professor Raines
is a Fellow of American College of Cardiology. He has published extensively
in the area of cardiovascular medicine. He holds seven acclaimed United
States patents for the Vasogram and Endogram technology. He most recently
retired as a Professor of Surgery from University of Miami, Florida, USA.
His role in InterCare will include working with the Research and
Development division of InterCare to continue to enhance and update the
Vasogram Technology for both United States and International
commercialization.
"Current cardiovascular research has confirmed that heart attack, stroke,
and most forms of peripheral vascular disease are caused by abnormalities
in the arterial wall. Vasogram is a new technology that has been
developed that allows physicians to assess the status of the arterial wall.
The test is rapid and painless and can be performed with no risk to the
patient in a physician's office. In addition, the cost of the testing is
competitive with other noninvasive cardiovascular tests," Dike said.
"For the first time, physicians will know how their patient's arteries
compare to healthy subjects of the same gender and age. Further, they will
know how their patient's arteries compare to subjects with known peripheral
and coronary arterial disease, which is the direct cause of over one
million deaths annually, generating over $100 billion direct and $180
billion. indirect treatment costs annually.
"The Vasogram technology will be most helpful in identifying subjects at
risk. With this identification treatment will start early and outcomes will
improve. Finally, this testing will target subjects who will benefit from
more expensive and perhaps invasive testing," Dike continued.
Initial estimates for procedures involving Vasogram technology and total
market opportunity, as estimated by McKinsey & Company, is between $300
million and $500 million of a total $1.4 billion market potential.
"Potential users of the Vasogram Technology include primary care
physicians, cardiologists, vascular specialists, clinics, and hospitals,"
Dike further said.
"Professor Raines brings to InterCare a wealth of scientific experience and
contacts, that we believe will help InterCare emerge as one of the industry
leaders in the area of Cardiovascular technology," said Dike. "We welcome
Jeff to InterCare DX family, and know that he will be a tremendous asset as
we begin officially to commercialize the Vasogram technology worldwide,"
Dike said.
"I am very thrilled to be working with Dr. Dike and the InterCare team in
further developing new technologies in the field of cardiovascular
medicine, as well as enhancing the Vasogram technology thereby making my
Vasogram dream a reality," said Professor Raines.
About InterCare DX
InterCare DX, Inc. an affiliate of Meridian Holdings, Inc. (OTC BB: MRDH),
developed and markets under an exclusive value-added reseller agreement
with Meridian Holdings, Inc., InterCare Clinical Explorer (TM) (ICE(TM)),
an innovative, robust and totally scalable software application designed to
integrate every aspect of the healthcare enterprise. InterCare provides
implementation and support for the ICE(TM) software, which is used to
document and track inpatient and outpatient diagnoses and treatment
modalities in various healthcare environments, ranging from individual
practices to entire hospital systems. The Company by initiating
commercialization of the Vasogram Technology, will be one of the few
technology companies with a unique cardiovascular diagnostics device in the
market that is backed by extensive scientific studies and publications. For
more information about the company and its products and services, visit
www.intercare.com.
NOTE: Statements in this news release that are not purely historical are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934 and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and any amendments thereto.
Material that is forward-looking may contain statements about expected
future events and/or financial results that are forward-looking in nature.
Editors and investors are cautioned that such forward-looking statements
invoke risk and uncertainties that may cause the Company's results to
differ from such forward-looking statements. These include, but are not
limited to, economic, competitive, governmental, technological, and other
factors discussed in the statements and/or in the Company's filings with
the Securities and Exchange Commission.
CONTACT:
Anthony C. Dike, MD
Chairman & CEO
InterCare DX, Inc.
213-627-8878
www.intercare.com
*** end of story ***
